Ascendis Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ascendis Pharma (ASND).

Price Target Range — 10 Quarters

Analyst Consensus — 19 Analysts

19Buy

Consensus RatingBuy# Analysts19Avg. Consensus PT$301Upside to Avg. PT+33.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 25, 2026	Cantor Fitzgerald	Li Watsek	Maintained	Overweight	$300
Sep 15, 2026	Raymond James	Martin Auster	Downgrade	Strong Buy→Outperform	$287
Sep 2, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$304→$312
Sep 1, 2026	Morgan Stanley	Maxwell Skor	PT Cut	Overweight	$275→$273
Sep 1, 2026	Wedbush	Yun Zhong	Maintained	Outperform	$327
Aug 31, 2026	B of A Securities	Tazeen Ahmad	PT Cut	Buy	$306→$304
Aug 31, 2026	Jefferies	Kelly Shi	PT Cut	Buy	$333→$330
Aug 31, 2026	Stifel	Alex Thompson	PT Cut	Buy	$328→$326
Aug 31, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$345→$344
Aug 27, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Initiate	Buy	$345
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform	$319
Aug 14, 2026	TD Cowen	Yaron Werber	PT Raise	Buy	$325→$341
Aug 14, 2026	RBC Capital	Luca Issi	PT Raise	Outperform	$280→$290
Aug 14, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$345→$329
Jul 23, 2026	Morgan Stanley	Maxwell Skor	PT Raise	Overweight	$256→$275
Jul 7, 2026	RBC Capital	Luca Issi	PT Raise	Outperform	$275→$280
May 19, 2026	Citigroup	Eric Joseph	Initiate	Buy	$355
May 15, 2026	Evercore ISI Group	Josh Schimmer	PT Raise	Outperform	$324→$329
May 11, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$342→$345
May 8, 2026	Wells Fargo	Derek Archila	PT Cut	Overweight	$330→$326

More with Benzinga EdgeGet Access

Analyst Ratings News

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.

Avi Kapoor

PRO
Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287

Raymond James analyst Martin Auster downgrades Ascendis Pharma (NASDAQ:ASND) from Strong Buy to Outperform and maintains the price target from $287 to $287.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312

Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $304 to $312.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273

Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $275 to $273.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target

Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.

Benzinga Newsdesk

Ascendis Pharma AS

Ascendis Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

PRO
Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287

PRO
Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312

PRO
Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273

PRO
Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target

PRO
B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304

People Also Watch

People Also Watch

Ascendis Pharma AS

Ascendis Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

PRORaymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287

PROOppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312

PROMorgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273

PROWedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target

PROB of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304

People Also Watch

People Also Watch

PRO
Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287

PRO
Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312

PRO
Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273

PRO
Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target

PRO
B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304